Institut Curie

Running trials

• Not yet recruiting

  Real World Positioning of Tyrosine Kinase Inhibitors (TKIs) Within Systemic Treatment Strategies for Advanced Neuroendocrine Tumors (NETs)

  NCT07890012· Source

• Not yet recruiting

  Analysis of histological risk factors and biomarkers in paediatric retinoblastoma

  2024-515962-15-00· Phase 2· Source

• Not yet recruiting

  A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC

  2026-526300-67-00· Phase 3· Source

• Not yet recruiting

  Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas

  NCT07924384· Source

• Recruiting

  A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

  NCT07700758· Phase 2· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Source

• Not yet recruiting

  Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.

  NCT07853105· Phase 1/2· Source

• Not yet recruiting

  Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA

  2026-525463-40-00· Phase 1/2· Source

• Recruiting

  A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

  NCT07768189· Phase 3· Source

• Not yet recruiting

  Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

  NCT07717450· Phase 3· Source

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Source

• Not yet recruiting

  Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

  NCT07340619· Phase 2· Source

• Recruiting

  A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

  NCT07465757· Phase 2· Source

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Source

• Recruiting

  A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT07680764· Phase 2· Source

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  NCT07680790· Phase 3· Source

• Not yet recruiting

  Reduction of treatment after Complete Response in Advanced Hormone-Sensitive Breast Cancer

  2026-526319-12-00· Phase 3· Source

• Not yet recruiting

  Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

  NCT07151586· Phase 2· Source

• Not yet recruiting

  Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2

  2026-525759-96-00· Phase 4· Source

• Recruiting

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Phase 3· Source

• Not yet recruiting

  Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

  NCT07747506· Phase 2· Source

• Not yet recruiting

  Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy

  NCT07357948· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Source

• Active, not recruiting

  Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

  2025-524713-88-00· Phase 2· Source

• Recruiting

  A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

  NCT07659782· Phase 2· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

  NCT07630974· Phase 1/2· Source

• Recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  NCT07365241· Phase 3· Source

• Not yet recruiting

  Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers

  NCT07437287· Phase 2/3· Source

• Recruiting

  Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

  NCT07489066· Phase 2· Source

• Not yet recruiting

  MOST-Express – A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients.

  2025-522058-38-00· Phase 2· Source

• Active, not recruiting

  A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.

  2023-503298-39-00· Phase 3· Source

• Recruiting

  A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

  NCT07365319· Phase 2/3· Source

• Recruiting

  Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

  NCT07486817· Phase 2· Source

• Not yet recruiting

  Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy_POG

  2025-523610-83-00· Phase 4· Source

• Recruiting

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Phase 3· Source

• Recruiting

  Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

  NCT07264075· Phase 3· Source

• Recruiting

  MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitor plus aromatase inhibitor-based endocrine treatment and with homologous recombination deficiency, oncogenic driver activation and/or other molecular alterations associated with replication stress (RS)

  NCT05986071· Phase 1/2· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  NCT07225270· Phase 3· Source

• Recruiting

  A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

  NCT07549321· Phase 2/3· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Source

• Recruiting

  Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.

  NCT07303387· Phase 2· Source

• Recruiting

  An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with selected solid tumors.

  2024-519788-16-00· Phase 2· Source

• Recruiting

  Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)

  NCT07043543· Source

• Not yet recruiting

  Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.

  NCT07111117· Phase 2· Source

• Recruiting

  Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

  NCT07371585· Phase 2· Source

• Recruiting

  Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line treatment – A non-comparative, randomized phase II PANORAMIX GERCOR G-116 PRODIGE 105 study

  2024-517766-41-00· Phase 2· Source

• Recruiting

  Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

  NCT07193394· Phase 2· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

  NCT07288177· Phase 2· Source

• Recruiting

  Neoadjuvant Darovasertib in Primary Uveal Melanoma

  NCT07015190· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer67 recruiting
• Childhood cancers41 recruiting
• Metastatic breast cancer34 recruiting
• Sarcoma16 recruiting
• Triple-negative breast cancer15 recruiting
• Head and neck cancer14 recruiting
• Prostate cancer14 recruiting
• Ovarian cancer13 recruiting
• Pancreatic cancer10 recruiting
• Colorectal cancer9 recruiting
• Gastric and esophageal cancer9 recruiting
• Endometrial cancer8 recruiting
• Liver and biliary tract cancer8 recruiting
• Melanoma6 recruiting
• Neuroblastoma6 recruiting
• Multiple myeloma5 recruiting
• Bladder cancer4 recruiting
• Mantle cell lymphoma4 recruiting
• Cervical cancer3 recruiting
• Kidney cancer3 recruiting
• Acute myeloid leukemia2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Follicular lymphoma2 recruiting
• Thyroid cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Glioblastoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Neuroendocrine tumours1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC

  2025-522867-13-00· Phase 2· Source

• Recruiting

  A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  NCT07226843· Phase 1· Source

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· Source

• Completed

  A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations

  2025-521480-12-00· Phase 1· Source

• Active, not recruiting

  Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

  2025-521115-40-00· Phase 2· Source

• Completed

  A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lung cancer that cannot be completely cured.

  2024-519651-28-00· Phase 1· Source

• Active, not recruiting

  A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

  NCT06521567· Phase 1/2· Source

• Completed

  KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer

  NCT05846516· Phase 1· Source

• Completed

  N/A

  2024-513121-22-00· Phase 2· Source

• Completed

  M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors

  2023-505431-12-00· Phase 1· Source

• Active, not recruiting

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· Phase 2· Source

• Completed

  Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

  NCT06735781· Source

• Completed

  Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study

  NCT06599463· Source

• Completed

  Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

  NCT05652868· Phase 1/2· Source

• Terminated

  A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer

  NCT06162351· Phase 2· Source

• Completed

  "TOPOLOGY" : A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer

  2022-501507-27-00· Phase 2· Source

• Completed

  Atezolizumab plus RP1 oncolytic immunotherapy in the NeoAdjuvant setting of Triple-Negative Breast Cancer

  2022-502311-12-00· Phase 2· Source

• Completed

  A Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy in Participants with First-line Stage IV or Recurrent NSCLC

  2022-503007-22-00· Phase 2· Source

• Active, not recruiting

  Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  2023-503428-24-00· Phase 2· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· Phase 2· Source

• Completed

  A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma.

  NCT04718675· Phase 1· Source

• Completed

  Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

  NCT06660147· Source

• Completed

  Study of DF6215 in Patients With Advanced Solid Tumors

  NCT06108479· Phase 1· Source

• Terminated

  Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

  NCT05932667· Phase 2· Source

• Completed

  Milademetan and fulvestrant in GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer patients (DEMETER)

  2022-502360-21-00· Phase 2· Source

• Completed

  A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

  NCT05665530· Phase 1· Source

• Completed

  Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  2022-502196-31-00· Phase 2/3· Source

• Completed

  A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

  NCT05909904· Phase 2· Source

• Completed

  Multicentric randomized phase I/IIa trial of the safety and immunogenicity of a therapeutic HPV DC targeting vaccine in patients with Human papillomavirus (HPV)-positive oropharyngeal cancer (HPV.DCVax)

  2022-502930-25-00· Phase 1/2· Source

• Completed

  A study to investigate the safety and tolerability of intravenous QEQ278 in patients with advanced solid tumors

  2022-500540-38-00· Phase 1· Source

• Completed

  Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

  NCT03744468· Phase 1/2· Source

• Completed

  A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

  NCT05635708· Phase 2· Source

• Completed

  Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies

  NCT05577182· Phase 1· Source

• Completed

  Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)

  NCT05429502· Phase 1/2· Source

• Completed

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· Phase 3· Source

• Completed

  Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  NCT05287113· Phase 2· Source

• Active, not recruiting

  A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT05424822· Phase 1· Source

• Completed

  Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

  NCT06525675· Source

• Completed

  Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)

  NCT05282901· Phase 2· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

  NCT05186974· Phase 2· Source

• Terminated

  A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

  NCT05269355· Phase 2/3· Source

• Active, not recruiting

  A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

  NCT05307705· Phase 1· Source

• Completed

  An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

  2023-508954-25-00· Phase 1/2· Source

• Completed

  Comparative Study of Diagnostic and Prognosis Biomarkers of Prostate Cancer in Liquid Biopsy (HOPE)

  NCT05141383· Source

• Completed

  Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)

  NCT05308966· Source

• Completed

  A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

  NCT05249426· Phase 1· Source

• Completed

  Rhabdoid Tumors Cellular Architecture by Single-cell Analyses (InnovRT-2)

  NCT04987476· Source

• Completed

  Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumours

  2024-511071-16-00· Phase 1· Source

• Active, not recruiting

  Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

  NCT05486182· Phase 4· Source

• Completed

  Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients

  NCT04912687· Source

Trial sites

• Curie Institute0 trials
• Institut Curie401 trials
• Institut Curie - Centre D'Oncologie SIREDO0 trials
• Institut Curie, Departement d'Oncologie Medicale1 trial
• Institut Curie /ID# 1249021 trial
• Institut Curie /ID# 2070460 trials
• Institut Curie /ID# 2234751 trial
• Institut Curie /ID# 2258291 trial
• Institut Curie /ID# 2401410 trials
• Institut Curie /ID# 2611270 trials
• Institut Curie /ID# 2694200 trials
• Institut Curie /ID# 2713950 trials
• Institut Curie /ID# 2776230 trials
• Institut Curie - Oncologie Medicale1 trial
• Institut Curie Paris8 trials
• Institut Curie - Paris - Oncologie medicale0 trials
• Institut Curie - Section Medicale1 trial
• Institut Curie - Service d'oncologie médicale0 trials
• Institut Curie - Service d'oncologie pédiatrique0 trials
• Institut Curie (Site 0112)0 trials
• Institut Curie (Site 0166)1 trial
• Institut Curie (Site 0237)1 trial
• Institut Curie (Site 0250)0 trials
• Institut Curie (Site 0325)0 trials
• Institut Curie (Site 0350)0 trials
• Institut Curie (Site 0400)0 trials
• Institut Curie (Site 0500)0 trials
• Institut Curie (Site 0900)0 trials
• Institut Curie (Site 0909)0 trials
• Institut Curie (Site 1152)1 trial
• Institut Curie (Site 3101)0 trials
• Institut Curie (Site 3903)0 trials
• Institut Curie, thoracic oncology department1 trial
• Institute Curie1 trial
• Oncologie Médicale - Institut Curie1 trial
• Paris - Institut Curie2 trials
• Service de Chirurgie Digestive, Institut Curie1 trial
• service d'oncologie pédiatrique, institut Curie1 trial
• Institut Curie110 trials
• Institute Curie1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Lung cancer240 works · 155 trials
• Ovarian cancer101 works · 33 trials
• Sarcoma74 works · 35 trials
• Metastatic breast cancer64 works · 63 trials
• Melanoma47 works · 26 trials
• Triple-negative breast cancer42 works · 29 trials
• Neuroblastoma32 works · 15 trials
• Childhood cancers21 works · 79 trials
• Endometrial cancer15 works · 16 trials
• Follicular lymphoma5 works · 8 trials